3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
8
Terminated
4
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Breast Neoplasms
2
Rhabdomyosarcoma
1
Retinoblastoma
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, AIDS-Related
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia
1
Infiltrating Bladder Urothelial Carcinoma
1
Hodgkin Disease
1
HER2-positive Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Blast Crisis
1
Amyloidosis
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Adenocarcinoma of Lung
1
Interventions
Carboplatin
85
pembrolizumab
78
Pemetrexed
68
Cisplatin
56
Paclitaxel
45
osimertinib
41
Nivolumab
40
durvalumab
37
Docetaxel
33
atezolizumab
20
Gemcitabine
18
Radiotherapy
17
Radiosurgery
16
amivantamab
15
Ipilimumab
15
130-nm albumin-bound paclitaxel
14
Taxes
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
12
Crizotinib
11
lazertinib
9
Radiation
9
Immunoglobulin G
9
Drug Therapy
9
Disulfides
9
Bevacizumab
9
tislelizumab
8
cemiplimab
8
alectinib
8
Erlotinib Hydrochloride
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Non-Small-Cell Lung
×
pegfilgrastim
×
Clear all
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts